Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ichikawa, Takehiro ^a   Sato, Fumiaki ^a   Terasawa, Kazuya ^a   Tsuchiya, Soken ^a   Toi, Masakazu ^a   Tsujimoto, Gozoh ^a   Shimizu, Kazuharu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; CYCLIN E2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOCORTIN 5; LUCIFERASE; MICRORNA; MICRORNA 26A; MICRORNA 30B; RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN26A MICRORNA, HUMAN; MIRN30 MICRORNA, HUMAN; MONOCLONAL ANTIBODY;

3' UNTRANSLATED REGION; ALGORITHM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CCNA1 GENE; CCNE2 GENE; CDC7 GENE; CELL ASSAY; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION PROFILING; GENETIC SCREENING; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; NUCLEOTIDE BINDING SITE; POSTTRANSCRIPTIONAL GENE SILENCING; REPORTER GENE; S PHASE CELL CYCLE CHECKPOINT; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MICRORNAS; RECEPTOR, ERBB-2;

EID: 84857582036     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031422     Document Type: Article

References (39)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
2. Hynes NE, Stern DF, (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184.
3. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, et al. (1995) Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75: 1320-1326.
4. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, et al. (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708.
5. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, et al. (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
7. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274.
8. Nishimura R, Okumura Y, Arima N, (2008) Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer 15: 57-64.
9. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
10. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808.
11. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N, (2008) Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9: 76.
12. Sato F, Tsuchiya S, Terasawa K, Tsujimoto G, (2009) Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One 4: e5540.
13. Terasawa K, Ichimura A, Sato F, Shimizu K, Tsujimoto G, (2009) Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS J 276: 3269-3276.
14. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, et al. (2011) MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 6: e16435.
15. Ito T, Tanaka E, Kadowaki T, Kan T, Higashiyama M, et al. (2007) An ultrasensitive new DNA microarray chip provides gene expression profiles for preoperative esophageal cancer biopsies without RNA amplification. Oncology 73: 366-375.
16. Qian B, Katsaros D, Lu L, Preti M, Durando A, et al. (2009) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 117: 131-140.
17. Kastl L, Brown I, Schofield AC, (2011) miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat.
18. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903.
19. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086.
20. Liang Z, Wu H, Xia J, Li Y, Zhang Y, et al. (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79: 817-824.
21. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, et al. (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794.
22. Marches R, Uhr JW, (2004) Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer 112: 492-501.
23. Dubska L, Andera L, Sheard MA, (2005) HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS Lett 579: 4149-4158.
24. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, et al. (2007) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26: 7590-7595.
25. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
26. Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, et al. (2009) Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 8: 172-175.
27. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
28. Zhang B, Liu XX, He JR, Zhou CX, Guo M, et al. (2011) Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32: 2-9.
29. Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, et al. (2011) A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 29: 794-801 e791.
30. Gao W, Shen H, Liu L, Xu J, Xu J, et al. (2011) MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 137: 557-566.
31. Gudas JM, Payton M, Thukral S, Chen E, Bass M, et al. (1999) Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol 19: 612-622.
32. Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, et al. (2011) Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 108: 3761-3766.
33. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, et al. (2011) MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 17: 2725-2733.
34. Boominathan L, (2010) The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev 29: 613-639.
35. Kanehisa M, (2011) KEGG pathway database.
36. Le XF, Pruefer F, Bast RC Jr, (2005) HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4: 87-95.
37. Rozowsky J, Euskirchen G, Auerbach RK, Zhang ZD, Gibson T, et al. (2009) PeakSeq enables systematic scoring of ChIP-seq experiments relative to controls. Nat Biotechnol 27: 66-75.
38. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, et al. (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202-4212.
39. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, et al. (2008) MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7: 1-9.